Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Kirby Institute

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 1986-01-01

Employees: 101

Market Cap: -

Website: https://kirby.unsw.edu.au

Clinical Trials

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Phase 3

Completed

Conditions: Hepatitis C, Acute

Interventions: Drug: Paritaprevir/ritonavir/ombitasvir
Drug: Glecaprevir/pibrentasvir
Drug: Dasabuvir
Drug: Ribavirin

First Posted Date: 2015-12-17

Last Posted Date: 2022-08-22

Lead Sponsor: Kirby Institute

Target Recruit Count: 83

Registration Number: NCT02634008

Locations: 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia

and more 8 locations

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: SOF/VEL for 12 weeks
Drug: SOF/VEL for 6 weeks

First Posted Date: 2015-12-09

Last Posted Date: 2021-11-24

Lead Sponsor: Kirby Institute

Target Recruit Count: 222

Registration Number: NCT02625909

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇦🇺
Kirketon Road Centre, Sydney, New South Wales, Australia

and more 22 locations

A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection

Phase 4

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: "3D" regimen
Drug: "3D" regimen with ribavirin

First Posted Date: 2015-07-15

Last Posted Date: 2019-06-13

Lead Sponsor: Kirby Institute

Target Recruit Count: 87

Registration Number: NCT02498015

Locations: 🇦🇺
The Kirby Institute, University of New South Wales Australia, Sydney, New South Wales, Australia

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Placebo
Drug: vorapaxar

First Posted Date: 2015-03-20

Last Posted Date: 2019-03-06

Lead Sponsor: Kirby Institute

Target Recruit Count: 65

Registration Number: NCT02394730

Locations: 🇺🇸
Georgetown University Hospital, Georgetown, Maryland, United States
🇺🇸
Hennepin County Medical Centre, Minneapolis, Minnesota, United States
🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia

and more 4 locations

A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: Sofosbuvir (SOF)/GS-5816

First Posted Date: 2015-01-12

Last Posted Date: 2019-02-27

Lead Sponsor: Kirby Institute

Target Recruit Count: 103

Registration Number: NCT02336139

Locations: 🇦🇺
The Kirby Institute, Sydney, New South Wales, Australia

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism

Phase 4

Withdrawn

Conditions: Hepatitis C, Chronic

Interventions: Drug: DCV/ASV/BCV

First Posted Date: 2014-11-18

Last Posted Date: 2016-06-03

Lead Sponsor: Kirby Institute

Registration Number: NCT02292966

Locations: 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia

PrEP Demonstration Project (PRELUDE Study)

Phase 4

Completed

Conditions: HIV

Interventions: Drug: emtricitabine/tenofovir disoproxil fumarate

First Posted Date: 2014-08-01

Last Posted Date: 2019-12-02

Lead Sponsor: Kirby Institute

Target Recruit Count: 327

Registration Number: NCT02206555

Locations: 🇦🇺
RPA Sexual Health, Camperdown, New South Wales, Australia
🇦🇺
Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia
🇦🇺
St Vincent's Hospital HIV, Immunology and Infectious Disease Unit, Darlinghurst, New South Wales, Australia

and more 2 locations

DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)

Phase 4

Completed

Conditions: Hepatitis C

Interventions: Drug: Sofosbuvir and ribavirin

First Posted Date: 2014-06-05

Last Posted Date: 2018-09-21

Lead Sponsor: Kirby Institute

Target Recruit Count: 20

Registration Number: NCT02156570

Locations: 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia

and more 2 locations

Control and Elimination Within Australia of Hepatitis C From People Living With HIV

Conditions: HIV
Hepatitis C
HIV-HCV Coinfection

First Posted Date: 2014-04-03

Last Posted Date: 2021-09-08

Lead Sponsor: Kirby Institute

Target Recruit Count: 492

Registration Number: NCT02102451

Locations: 🇦🇺
Dr Doong's Surgery, Burwood, New South Wales, Australia
🇦🇺
Blue Mountains Sexual Health and HIV Centre, Katoomba, New South Wales, Australia
🇦🇺
Sydney Sexual Health Centre, Sydney, New South Wales, Australia

and more 15 locations

Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients

Completed

Conditions: Chronic Hepatitis C Infection

First Posted Date: 2014-02-19

Last Posted Date: 2024-03-06

Lead Sponsor: Kirby Institute

Target Recruit Count: 100

Registration Number: NCT02065999

Locations: 🇦🇺
St Vincent's Hospital, Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy